DAMORA THERAPEUTICS, INC. Restructuring Charges
DAMORA THERAPEUTICS, INC. (DMRA) reported Restructuring Charges of $968.00 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-19.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:RestructuringCharges · last filed 2026-03-19
- DAMORA THERAPEUTICS, INC. restructuring charges for the quarter ending 2024-12-31 was $0.00.
- DAMORA THERAPEUTICS, INC. restructuring charges for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- DAMORA THERAPEUTICS, INC. restructuring charges for the quarter ending 2024-06-30 was -$2.43M.
- DAMORA THERAPEUTICS, INC. restructuring charges for the quarter ending 2024-03-31 was $3.40M.
- DAMORA THERAPEUTICS, INC. restructuring charges for fiscal 2024 was $968.00K, a 71.93% decline from fiscal 2023.
- DAMORA THERAPEUTICS, INC. restructuring charges for fiscal 2023 was $3.45M.
| Period end | Restructuring Charges | Restructuring Charges 1 month | Restructuring Charges 3 month | Restructuring Charges 6 month | Restructuring Charges 9 month | Restructuring Charges 12 month |
|---|---|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $0.00 derived: sum of 2 quarters · filed 2026-03-19 | -$2.43M derived: sum of 3 quarters · filed 2026-03-19 | $968.00K 10-K · filed 2026-03-19 | ||
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-01 | -$2.43M derived: sum of 2 quarters · filed 2024-11-01 | $968.00K 10-Q · filed 2024-11-01 | |||
| 2024-06-30 | $4.40M 10-Q · filed 2024-11-01 | -$2.43M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $968.00K 10-Q · filed 2024-08-12 | |||
| 2024-05-31 | $4.40M 10-K · filed 2025-03-19 | |||||
| 2024-03-31 | $3.40M 10-Q · filed 2024-04-29 | |||||
| 2023-12-31 | $3.45M 10-K · filed 2025-03-19 | |||||
| 2023-09-30 | $4.50M 10-Q · filed 2024-08-12 | $2.70M 10-Q · filed 2023-11-06 | ||||
| 2023-09-26 | $3.40M 10-Q · filed 2023-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |